Vor Biopharma Inc. financial data

Symbol
VOR on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
100 Cambridgepark Drive, Suite 101, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 720 % -52.1%
Debt-to-equity 40 % +80.3%
Return On Equity -101 % -88.2%
Return On Assets -72.2 % -64.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 68.7M shares +1.28%
Common Stock, Shares, Outstanding 68.7M shares +1.3%
Entity Public Float 136M USD +17.7%
Common Stock, Value, Issued 7K USD 0%
Weighted Average Number of Shares Outstanding, Basic 68.5M shares +1.27%
Weighted Average Number of Shares Outstanding, Diluted 68.5M shares +1.27%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 88.9M USD -1.79%
General and Administrative Expense 29.1M USD -9.39%
Operating Income (Loss) -118M USD +3.78%
Nonoperating Income (Expense) 5.54M USD -22.3%
Net Income (Loss) Attributable to Parent -112M USD +2.64%
Earnings Per Share, Basic -1.64 USD/shares +12.8%
Earnings Per Share, Diluted -1.64 USD/shares +12.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 52.8M USD +17.3%
Marketable Securities, Current 10M USD -91.3%
Cash, Cash Equivalents, and Short-term Investments 62.8M USD
Other Assets, Current 285K USD -57.3%
Assets, Current 67.3M USD -59.1%
Property, Plant and Equipment, Net 7.47M USD -31%
Operating Lease, Right-of-Use Asset 36.3M USD -12%
Other Assets, Noncurrent 2.51M USD -38.5%
Assets 116M USD -48%
Accounts Payable, Current 1.32M USD +0.54%
Employee-related Liabilities, Current 4.14M USD -3.07%
Accrued Liabilities, Current 8.85M USD -13.8%
Liabilities, Current 14.3M USD -6.78%
Operating Lease, Liability, Noncurrent 28.7M USD -12.7%
Liabilities 43M USD -10.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 68K USD
Retained Earnings (Accumulated Deficit) -426M USD -35.8%
Stockholders' Equity Attributable to Parent 73M USD -58.3%
Liabilities and Equity 116M USD -48%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -30.5M USD -25.5%
Net Cash Provided by (Used in) Financing Activities 96K USD -96.2%
Net Cash Provided by (Used in) Investing Activities 44M USD +577%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 68.7M shares +1.28%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 13.6M USD
Deferred Tax Assets, Valuation Allowance 104M USD +52.8%
Deferred Tax Assets, Gross 116M USD +44.9%
Operating Lease, Liability 32.9M USD -10.2%
Depreciation 3.6M USD +11.2%
Payments to Acquire Property, Plant, and Equipment 114K USD +21.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -112M USD +2.18%
Lessee, Operating Lease, Liability, to be Paid 46.8M USD -11.9%
Property, Plant and Equipment, Gross 18.2M USD +1.14%
Operating Lease, Liability, Current 4.16M USD +11.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 6.65M USD +1.11%
Lessee, Operating Lease, Liability, to be Paid, Year One 6.59M USD +4.37%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 11.1M USD -21.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 6.68M USD +0.56%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 6.88M USD +3.01%
Operating Lease, Payments 1.64M USD +6.15%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 11.7M USD -0.6%
Share-based Payment Arrangement, Expense 10M USD -34.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%